Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

Basic and translational research in this field aims to repair heart injury and prevent the heart failure that often follows a heart attack.

Bacteria use molecular machines to move proteins, including toxins, across cell membranes. M. tuberculosis, which kills more than 1 million people a year, uses the ESX-4 type VII secretion system to transports its potent exotoxin.
Preclinical experiments show how to identify non-responding tumors and improve their response to immunotherapy, using two investigational new drugs that are permitted for human use. Physicians could immediately start investigational research in patients to test the effectiveness of this personalized approach.

The latest grant for Andrea Cherrington, M.D., is $21.7 million over five years from the National Institute on Minority Health and Health Disparities to improve chronic disease outcomes for Black Americans in the Deep South.

The life sciences fund will focus on development of early-stage UAB technologies and startup companies.

Release of TT-10 from nanoparticles improved heart function after a heart attack, accompanied by increased cardiomyocyte proliferation and smaller infarct size.

Lupus, an autoimmune disease that can attack any part of the body, can be confounding because patients often respond differently to the same treatment, and they vary widely in the severity of their symptoms.

Fecal-dominant donor microbes in the recipient patients after fecal microbe transplantation did not correlate with response to anti-PD-1 therapy.

Limiting neuroinflammation may represent a promising new approach to treat neurological diseases driven by neuroinflammation, such as stroke, spinal cord injury and neuropathic pain.

Yabing Chen, Ph.D., is the first researcher at the Birmingham VA to receive this highest honor for a non-physician scientist.

Page 1 of 39